Editas Medicine Announces Transition of Chief Financial Officer
21 déc. 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D.,...
Editas Medicine Names Cynthia Collins to Board of Directors
10 déc. 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of...
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
02 déc. 2018 19h35 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
30 nov. 2018 07h30 HE
|
Editas Medicine, Inc.
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass., Nov. 30,...
Editas Medicine Announces Third Quarter 2018 Results and Update
07 nov. 2018 16h01 HE
|
Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
31 oct. 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Grows Scientific Leadership with Two New Appointments
01 oct. 2018 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene...
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
10 sept. 2018 13h58 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit...
Editas Medicine Announces Transition of Chief Medical Officer
27 août 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D.,...
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
16 août 2018 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA...